Reports & Briefings

In most cases, local governments have neither the competence nor the economies of scale to deliver broadband as well as private ISPs. So, favoring government-owned networks wastes societal resources, creates unfair competition, and is frequently unsustainable in the long run.

The UK stands at a critical moment when embracing digital transformation, AI, and data innovation is not just an opportunity but also a necessity. By implementing forward-thinking policies, the UK can not only drive economic growth but also position itself as a global leader in emerging technologies.

Neo-Brandeisians aim to reinvigorate the Robinson-Patman Act to protect small businesses. But the act doesn’t address any anticompetitive conduct that isn’t already covered by the Sherman Act, and enforcing it will only harm consumers and limit growth. Rather than repeat history’s mistakes, the next Congress should repeal the act once and for all.

AI has the potential to transform drug development by enhancing productivity across the entire development pipeline, boosting biopharmaceutical innovation, accelerating the delivery of new therapies, and fostering competition to help improve public health outcomes.

For policymakers to bolster the global competitiveness of their nations and regions, they first must know where they stand. This report benchmarks the 87 regions of India and the United States using 13 commonly available indicators of strength in the knowledge economy, globalization, and innovation capacity.

Information and communications technology (ICT) is driving global economic growth and economic opportunity. Many countries are taking effective steps to deploy digital infrastructure, enhance citizens’ digital skills and literacy, empower women and disabled citizens to leverage digital tools, and helping small- and medium-sized enterprises take advantage of digital technologies.

The scope and magnitude of the trade-off between immediate savings from lower drug prices and future health benefits from clinical development remain poorly understood and quantified. To support rigorous evaluations and inform evidence-based policymaking, it is crucial to invest in this area through research grants and improved access to federal and private data.

There is a need for more rigorous evidence and more recent, high-quality data to inform biopharmaceutical policymaking by shedding light on the relationship between pharmaceutical firms’ expectations of financial returns from new drugs and their ability to invest in further R&D to discover future generations of drugs.

In its bid for tech sovereignty, the EU has been aggressively targeting U.S. firms and industries with unfair protectionist policies. This cannot stand. To move forward into a new era of deeper transatlantic trade integration, America must first demand a level playing field.

Some conservatives have grievances with “Big Tech” companies and would marshal the power of government to punish them. But the policy proposals stemming from this conservative “techlash” would have significant costs for consumers, businesses, and the economy.